Technology and Scienceupdated 24m ago2 min read
Isomorphic Labs Raises $5 Billion Series C Co-Led by Greenoaks and Sequoia Capital
8outlets comparedWhere the coverage agrees
5 Other2 Western Mainstream1 Western AlternativeThis article is an automated aggregation of coverage from news outlets. Our editorials offer in-depth analysis curated by the NewsCord team.
Isomorphic Labs raises $5 billion Series C co-led by Greenoaks and Sequoia, with Alphabet participation. Round aims to move AI-designed drug candidates into clinical trials and expand its pipeline.
Save coverage image
8 outlets in this story. Read their headlines below.
$5B Series C for AI drugs
Isomorphic Labs announced it raised $5 Billion in Series C financing, co-led by Greenoaks and Sequoia Capital with Andreessen Horowitz and continued investment from Alphabet. Isomorphic said the funding will scale its proprietary drug design engine, IsoDDE, and its therapeutic candidate pipeline designed with AI, while also supporting “scalable AI-first translational and clinical development infrastructure” to advance drug candidates to clinical trials. Isomorphic’s CEO Demis Hassabis said, “This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients.”
Isomorphic’s President Max Jaderberg added, “Every week we are making repeatable scientific advancements enabled by our models,” and said those translate into “better molecular profiles” with the potential to become new medicines. Isomorphic said its IsoDDE unifies foundational simulation AI models that work across multiple therapeutic areas and drug modalities, and it described its program as yielding “positive preclinical results” in oncology and immunology.
Backers and prior $2.1B
Isomorphic said the Series C round included participation from all existing investors, including Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. The $5 billion Series C came about six months after Isomorphic raised a $2.1 billion Series B led by Thrive, and Alphabet made a significant investment. Isomorphic’s endgame is to move its first drug candidates into clinical trials, and the company declined to share its valuation.
Isomorphic raised $5 billion in a series C round as the second time in six months it pulled off a multibillion-dollar financing, after the May $2.1 billion series B. The Series C funding comes on the heels of the $2.1 billion Series B round in May and will be used to continue developing the drug-design engine and expand into more types of medicine.
Preclinical promise, clinical test
Isomorphic uses AI to design medicines through its proprietary engine, IsoDDE, which predicts drug properties and refines candidates before scientists make and test them. Isomorphic has reported only “positive” preclinical results, without detailed data, and has yet to show how IsoDDE-generated candidates perform in humans. Isomorphic’s program has yielded “positive preclinical results” in oncology and immunology, and the lab has struck deals with Eli Lilly, Novartis, and Johnson & Johnson.
Isomorphic is still working toward the “acid test” of showing how drug candidates generated using IsoDDE perform in humans, and the company has yet to disclose detailed preclinical data beyond saying the results are “positive.” Isomorphic’s own announcement said it is “advancing a broad and ambitious drug design portfolio” through partnered programs and wholly-owned internal programs, and it said the new capital is meant to “set the stage for clinical entry.”